With this small molecule, published reports have demonstrated the therapeutic utility of SLC6A14 blockade in the treatment of multiple tumor types that are associated with upregulation of this transporter: breast cancer [72,73,74], pancreatic cancer [76,95], and colon cancer [69]. This evidence concerns the gene SLC6A14 and familial pancreatic carcinoma.